lenvatinib Mesylate
10mM in DMSO
- Product Code: 204298
CAS:
857890-39-2
| Molecular Weight: | 522.96 g./mol | Molecular Formula: | C₂₁H₁₉N₄O₄Cl.CH₄O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Used in the treatment of several types of cancer, including differentiated thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma. It functions as a multi-kinase inhibitor, blocking key proteins involved in tumor angiogenesis, growth, and progression. Also approved for use in combination with other therapies, such as everolimus or pembrolizumab, to enhance efficacy in advanced kidney and endometrial cancers. Its targeted action helps slow tumor growth and improve progression-free survival in patients with specific genetic and tumor profiles.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿1,680.00 |
+
-
|
lenvatinib Mesylate
Used in the treatment of several types of cancer, including differentiated thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma. It functions as a multi-kinase inhibitor, blocking key proteins involved in tumor angiogenesis, growth, and progression. Also approved for use in combination with other therapies, such as everolimus or pembrolizumab, to enhance efficacy in advanced kidney and endometrial cancers. Its targeted action helps slow tumor growth and improve progression-free survival in patients with specific genetic and tumor profiles.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :